TY - JOUR
T1 - Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia
AU - Palmieri, Raffaele
AU - Buccisano, Francesco
AU - Maurillo, Luca
AU - Del Principe, Maria I.
AU - Paterno, Giovangiacinto
AU - Venditti, Adriano
AU - Martinelli, Giovanni
AU - Cerchione, Claudio
N1 - Publisher Copyright:
© 2020 ediZiOni Minerva Medica.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10
Y1 - 2020/10
N2 - Baseline cytogenetic/genetic features have been widely recognized to play a critical prognostic role in acute myeloid leukemia (AML) and have proven useful in designing risk-adapted treatment strategies. Nevertheless, to improve further the outcome of aML patients we are still in need of accurate methods to explore the quality of response and to adequately discriminate patients who are likely to relapse over time from those who are in deep and stable remission. in this view, is it well established that measurement of leukemic cells surviving chemotherapy (called measurable residual disease, MRD) during the course of treatment may be a reliable biomarker in predicting relapse. Detection of MRD relies on highly sensitive techniques, such as quantitative polymerase chain reaction and multiparametric flow cytometry, which, due to their levels of specificity and sensitivity, are increasingly included in the decision-making process of AML treatment. in the present manuscript, we will review the current techniques of Mrd investigation and their clinical contribution to aML management.
AB - Baseline cytogenetic/genetic features have been widely recognized to play a critical prognostic role in acute myeloid leukemia (AML) and have proven useful in designing risk-adapted treatment strategies. Nevertheless, to improve further the outcome of aML patients we are still in need of accurate methods to explore the quality of response and to adequately discriminate patients who are likely to relapse over time from those who are in deep and stable remission. in this view, is it well established that measurement of leukemic cells surviving chemotherapy (called measurable residual disease, MRD) during the course of treatment may be a reliable biomarker in predicting relapse. Detection of MRD relies on highly sensitive techniques, such as quantitative polymerase chain reaction and multiparametric flow cytometry, which, due to their levels of specificity and sensitivity, are increasingly included in the decision-making process of AML treatment. in the present manuscript, we will review the current techniques of Mrd investigation and their clinical contribution to aML management.
KW - Acute
KW - Myeloid
KW - Neoplasm
KW - Residual; Flow cytometry; Leukemia
UR - http://www.scopus.com/inward/record.url?scp=85097002991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097002991&partnerID=8YFLogxK
U2 - 10.23736/S0026-4806.20.07016-0
DO - 10.23736/S0026-4806.20.07016-0
M3 - Review article
C2 - 32955825
AN - SCOPUS:85097002991
VL - 111
SP - 386
EP - 394
JO - Minerva Medica
JF - Minerva Medica
SN - 0026-4806
IS - 5
ER -